Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 3Endocrine 3Thoracic 1Sarcoma 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1CNS 1

Conditions

Advanced Solid Tumor 3Mesothelioma 2Advanced Solid Tumors 2Stomach Neoplasms 1Solid Tumors 1Sarcoma 1Neuroendocrine Tumors 1Neoplasms 1Mesothelioma, Malignant 1Major Advanced Solid Tumors Other Than Colorectal 1Glioblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1ADVANCED SOLID TUMORS 1

Interventions

pembrolizumab 1olaparib 1fludarabine phosphate 1fludarabine 1Quality of Life 1Patient Reported Outcome Measures 1PM 01183 1Nivolumab 1Molecular Diagnostic Techniques 1Irinotecan 1Immunotherapy 1Drug Therapy 1Cyclophosphamide 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Tumors × PM 01183 × Other solid neoplasm × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡